Chronic adrenal insufficiency: genetic aspects of the disease
https://doi.org/10.52485/19986173_2022_4_132
Abstract
This review article provides current information on the pathogenetic and genetic features of primary adrenal insufficiency (1-HI) based on the analysis of available scientific articles indexed in PubMed and Web of Science. The aim of this article is to review the immunological and molecular genetic mechanisms of 1-HI development of various genesis. The diversity of etiological causes of adrenal cortical insufficiency has raised the need for the medical community to expand knowledge of proven gene mutations that lead to decreased adrenal function combined with lesions of various organs and systems. This review presents the latest data from the first genome-wide association study (GWAS) of 1-HI of autoimmune origin. The study showed associations of autoimmune 1-HI with risk loci variants PTPN22, CTLA4, LPP, BACH2, SH2B3, SIGLEC5, UBASH3A, and AIRE gene. Four previously unknown loci have been identified: LPP, SH2B3, SIGLEC5 and UBASH3A. 1-HI may be a component of autoimmune polyglandular syndromes type 1 and type 2 with a mutation in the AIRE gene. Despite the achievements of modern science, modern methods of genetic research allowing to establish the diagnosis of 1-HI, to clarify its pathogenetic mechanisms, and to individualize treatment are yet to be introduced into clinical practice.
About the Authors
L. Yu. Khamnueva
Irkutsk State Medical University
Russian Federation
Russian Federation
1 Krasnogo Vosstaniya str., Irkutsk, 664003
L. S. Andreeva
Irkutsk State Medical University
Russian Federation
Russian Federation
1 Krasnogo Vosstaniya str., Irkutsk, 664003
E. V. Chugunova
Irkutsk State Medical University
Russian Federation
Russian Federation
1 Krasnogo Vosstaniya str., Irkutsk, 664003
References
1. Mason A.S., Meade T.W., Lee J.A., Morris J.N. Epidemiological and clinical picture of Addison's disease. Lancet. 1968. 2(7571). 744-747. doi: 10.1016/s0140-6736(68)90948-3.
2. Lovås K., Husebye E.S. High prevalence and increasing incidence of Addison's disease in western Norway. Clin Endocrinol (Oxf). 2002. 56(6). 787-791. doi: 10.1046/j.1365-2265.2002.t01-1-01552.x.
3. Erichsen M.M., Lovås K., Skinningsrud B. et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab. 2009. 94(12). 4882-4890. doi: 10.1210/jc.2009-1368.
4. Olafsson A.S., Sigurjonsdottir H.A. Increasing prevalence of addison disease: results from a nationwide study. Endocr Pract. 2016. 22(1). 30-35. doi: 10.4158/EP15754.or.
5. Bleicken B., Hahner S., Ventz M., Quinkler M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci. 2010. 339(6). 525-531. doi: 10.1097/MAJ.0b013e3181db6b7a.
6. Guran T., Buonocore F., Saka N. et al. Rare causes of primary adrenal insufficiency: genetic and clinical characterization of a large nationwide cohort. J Clin Endocrinol Metab. 2016. 101(1). 284-292. doi: 10.1210/jc.2015-3250.
7. Heshmatzad K., Mahdieh N., Rabban A., Didban A., Rabbani B. The genetic perspective of familial glucocorticoid deficiency: in silico analysis of two novel variants. International journal of endocrinology. 2020. 2020:2190508. doi: 10.1155/2020/2190508.
8. Novoselova T.V., Chan L.F., Clark A.J.L. Pathophysiology of melanocortin receptors and their accessory proteins. Best Practice & Research Clinical Endocrinology & Metabolism. 2018. 32(2). 3–106. doi: 10.1016/j.beem.2018.02.002.
9. Flokas M.E., Tomani M., Agdere L., Brown B. Triple A syndrome (Allgrove syndrome): improving outcomes with a multidisciplinary approach. Pediatric health, medicine and therapeutics. 2019. 10. 99-106. doi: 10.2147/PHMT.S173081.
10. Jayant S.S., Gupta R., Agrawal K., Das L., Dutta P., Bhansali A. Triple A (Allgrove) syndrome due to AAAS gene mutation with a rare association of amyotrophy. Hormones (Athens). 2020. 22. doi: 10.1007/s42000-020-00217-7.
11. Prasad R., Hadjidemetriou I., Maharaj A. et al. Sphingosine -1- phosphate lyase mutations cause primary adrenal insufficiency and steroid resistant nephrotic syndrome. J Clin Invest. 2017. 127(3). 942-953. doi: 10.1172/JCI90171.
12. Lovric S., Saba J.D., Hildebrandt F. et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest. 2017. 127(3). 912-928. doi: 10.1172/JCI89626.
13. Ito M., Achermann J.C., Jameson J.L. A naturally occurring steroidogenie factor-1 mutation exhibits differential binding and activation of target genes. J Biol Chem. 2000. 275(41). 31708- 31714. doi: 10.1074/jbc.M002892200.
14. Domenice S., Zamboni Machado A., Moraes Ferreira F. et al. Wide spectrum of NR5A1 related phenotypes in 46, XY and 46, XX individuals. Birth Defects Res C Embryo Today. 2016. 108(4). 309-320. doi: 10.1002/bdrc.21145.
15. Suntharalingham J.P., Ishida M., Buonocore F., Del Valle I., Solanky N., Demetriou et al. Analysis of CDKN1C in fetal growth restriction and pregnancy loss. F1000Res. 2019. 8. 90. doi: 10.12688/f1000research.15016.2.
16. Chien Y., Rosal K., Chung B.C. Function of CYP11A1 in the mitochondria. Review Mol Cell Endocrinol. 2017. 441. 55-61. doi: 10.1016/j.mce.2016.10.030.
17. Maharaj A., Buonocore F., Meimaridou E. et al. Predicted benign and synonymous variants in CYP11A1 cause primary adrenal insufficiency through missplicing. J Endocr Soc. 2018. 3(1). 201-221. doi: 10.1210/js.2018-00130.
18. Addison T. On the constitutional and local effects of disease of the supra-renal capsules. Br Foreign Med Chir Rev. 1856. 404-413.
19. Saverino S., Falorni A. Autoimmune Addison's disease. Best Pract Res Clin Endocrinol Metab. 2020. 34(1). 101379. doi: 10.1016/j.beem.2020.101379.
20. Betterle C., Scarpa R., Garelli S., Morlin L., Lazzarotto F., Presotto F. et.al. Addison's disease: a survey on 633 patients in Padova. Eur J Endocrinol. 2013. 169(6). 773-784. doi: 10.1530/EJE-13-0528.
21. Hellesen A., Bratland E. The potential role for infections in the pathogenesis of autoimmune Addison's disease. Clin Exp Immunol. 2019. 195(1). 52-63. doi: 10.1111/cei.13207.
22. Hellesen A., Bratland E., Husebye E.S. Autoimmune Addison's disease - an update on pathogenesis. Ann Endocrinol. (Paris). 2018. 79(3). 157-163. doi: 10.1016/j.ando.2018.03.008.
23. Kahaly G.J, Frommer L. Polyglandular autoimmune syndromes. Journal of endocrinological investigation. 2018. 41(1). 91-98. doi: 10.1007/s40618-017-0740-9.
24. Meyer G., Neumann K., Badenhoop K., Linder R. Increasing prevalence of Addison's disease in German females: health insurance data 2008-2012. Eur J Endocrinol. 2014. 170(3). 367-373. doi: 10.1530/EJE-13-0756.
25. Husebye E.S., Anderson M.S., Kämpe O. Autoimmune polyendocrine syndromes. N Engl J Med. 2018. 378(12). 1132-1141. doi: 10.1056/NEJMra1713301.
26. Eisenbarth G.S., Gottlieb P.A. Autoimmune polyendocrine syndromes. N Engl J Med. 2004. 350(20). 2068-2079. doi: 10.1056/NEJMra030158.
27. Sollid L.M., Markussen G., Ek J., Gjerde H., Vartdal F., Thorsby, E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med. 1989. 169(1). 345-350. doi: 10.1084/jem.169.1.345.
28. Ueda H., Howson J.M. Esposito L., Heward J., Snook H., Chamberlain G. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003. 423(6939). 506-511. doi: 10.1038/nature01621.
29. Pham-Dobor G., Hanák L., Hegyi P., Márta K., Párniczky A., Gergics M. et al. Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III. Journal of endocrinological investigation. 2020. 43(9). 1-9. doi: 10.1007/s40618-020-01229-1.
30. Hansen M.P., Matheis N., Kahaly G.J. Type 1 diabetes and polyglandular autoimmune syndrome: a review. World J Diabetes. 2015. 6(1). 67-79. doi: 10.4239/wjd.v6.i1.67.
31. Kraus A.U., Penna-Martinez M., Shoghi F., Seidl C., Meyer G., Badenhoop K. HLA-dqb1 position 57 defines susceptibility to isolated and polyglandular autoimmunity in adults: interaction with gender. J Clin Endocrinol Metab. 2019. 104(6). 1907-1916. doi: 10.1210/jc.2018-01621.
32. Betterle C., Presotto F., Furmaniak J. Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults. Endocrinol Invest. 2019. 42(12). 1407-1433. doi: 10.1007/s40618-019-01079-6.
33. Røyrvik E.C, Husebye E.S. The genetics of autoimmune Addison disease: past, present and future. Nat Rev Endocrinol. 2022. 18(7). 399-412. doi: 10.1038/s41574-022-00653-y.
34. Falorni A., Brozzetti A., Perniola R. From genetic predisposition to molecular mechanisms of autoimmune primary adrenal insufficiency. Front Horm Res. 2016. 46. 115-132. doi: 10.1159/000443871.
35. Skov J., Höijer J., Magnusson P.K.E., Ludvigsson J.F., Kämpe O., Bensing S. Heritability of Addison's disease and prevalence of associated autoimmunity in a cohort of 112 100 Swedish twins. Endocrine. 2017. 58(3). 521-527. doi: 10.1007/s12020-017-1441-z.
36. Eriksson D., Røyrvik E.C., Aranda-Guillén M., Berger A.H., Landegre N., Artaza H. et al. GWAS for autoimmune Addison’s disease identifies multiple risk loci and highlights AIRE in disease susceptibility. Nat Commun. 2021. 12(1). 959. doi: 10.1038/s41467-021-21015-8.
37. Oelkers W. Adrenal insufficiency. N Engl J Med. 1996. 335 (16). 1206-1212. doi: 10.1056/NEJM199610173351607.
38. Husebye E.S., Pearce S.H., Krone N.P., Kämpe O. Adrenal Insufficiency. Lancet. 2021. 397(10274). 613-629. doi: 10.1016/S0140-6736(21)00136-7.
39. Engelen M., Kemp S., de Visser M., van Geel B.M., Wanders R.J.A., Aubourg P. et al. X-Linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012. 7.51. doi: 10.1186/1750-1172-7-51.
40. Betterle C., Presotto F., Furmaniak J. Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults. Journal of endocrinological investigation. 2019. 42(12). 1407-1433. doi: 10.1007/s40618-019-01079-6.
Review
For citations:
Khamnueva L.Yu., Andreeva L.S., Chugunova E.V. Chronic adrenal insufficiency: genetic aspects of the disease. Transbaikalian Medical Bulletin. 2022;(4):132-141. (In Russ.) https://doi.org/10.52485/19986173_2022_4_132
Views:
91
Email this article 